カテゴリ： GlobalData, アメリカ, 企業調査

Peregrine Pharmaceuticals Inc (PPHM)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Peregrine Pharmaceuticals Inc (PPHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013564
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Peregrine Pharmaceuticals Inc (Peregrine) is a biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment and diagnosis of cancer. The company’s products include Bavituximab, PGN650 and Cotara. Its Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid. Peregrine’s Cotara is for Phase III clinical development for the treatment of glioblastoma multiforme. The company utilizes technologies such as phosphatidylserine-targeting therapy for cancers and viral diseases and tumor necrosis therapy. It also has in-house cGMP manufacturing capabilities through its subsidiary located in the US. Peregrine is headquartered in Tustin, California, the US.

Peregrine Pharmaceuticals Inc (PPHM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Peregrine Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Equity Offering 15
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 22
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 23
Peregrine Pharmaceuticals Inc – Key Competitors 25
Peregrine Pharmaceuticals Inc – Key Employees 26
Peregrine Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Strategy And Business Planning 28
Jul 31, 2017: Peregrine Provides Strategic Update 28
Financial Announcements 30
Sep 11, 2017: Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments 30
Jul 14, 2017: Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments 32
Mar 13, 2017: Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments 35
Dec 12, 2016: Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments 37
Sep 08, 2016: Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments 39
Jul 14, 2016: Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments 41
Mar 09, 2016: Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments 43
Corporate Communications 45
Oct 24, 2017: Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices 45
Oct 19, 2017: Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices 46
Sep 11, 2017: Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices 47
Aug 11, 2017: Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations 48
Product News 49
09/06/2016: National Comprehensive Cancer Network Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals Bavituximab in Multiple Cancers 49
May 01, 2017: MilliporeSigma’s Mobius 2,000-liter Single-use Bioreactors to Expand Avid Bioservices’ Manufacturing Capabilities 50
01/20/2016: Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences 51
Clinical Trials 53
Nov 14, 2016: New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals PS-Targeting Antibodies in a Preclinical Melanoma Model 53
Oct 24, 2016: Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer 55
Oct 10, 2016: Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress 56
Sep 27, 2016: Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer 58
Sep 21, 2016: Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress 59
Apr 20, 2016: Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC) 60
Feb 25, 2016: Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab 61
Jan 11, 2016: Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers 62
Other Significant Developments 64
Jun 02, 2016: Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses 64
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Peregrine Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Peregrine Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 22
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 23
Peregrine Pharmaceuticals Inc, Key Competitors 25
Peregrine Pharmaceuticals Inc, Key Employees 26
Peregrine Pharmaceuticals Inc, Subsidiaries 27

★海外企業調査レポート[Peregrine Pharmaceuticals Inc (PPHM)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • The Second Cup Ltd.
    The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ironwood Pharmaceuticals Inc (IRWD)：企業の財務・戦略的SWOT分析
    Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Fuel Performance Solutions Inc (IFUE)：企業の財務・戦略的SWOT分析
    Summary Fuel Performance Solutions Inc (FPS), formerly International Fuel Technology Inc is an oil and gas company that develops liquid fuel additive formulations designed to enhance the performance of liquid hydrocarbon and bio-diesel fuels. The company offers products such as diesel, gasoline, bio …
  • PNC Wealth Management：企業の戦略・SWOT・財務情報
    PNC Wealth Management - Strategy, SWOT and Corporate Finance Report Summary PNC Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Dis-Chem Pharmacies Limited (DCP)：企業の財務・戦略的SWOT分析
    Dis-Chem Pharmacies Limited (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Icon Energy Ltd (ICN)：企業の財務・戦略的SWOT分析
    Summary Icon Energy Ltd (Icon Energy), formerly Icon Oil NL, is an oil and gas exploration and production company that acquires, explores, and develops oil and gas properties. The company's exploration tenements include ATP 855, PRL's 33-49, ATP 594, ATP 626, ATP 794, ATP 549 West, PEP 170, PEP 172, …
  • Bandera Electric Cooperative, Inc.：企業の戦略的SWOT分析
    Bandera Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Aprima Medical Software Inc：医療機器：M&Aディール及び事業提携情報
    Summary Aprima Medical Software Inc (Aprima) is a healthcare information technology service provider. The company’s solutions include EHR, practice management, and revenue cycle management. Its EHR solutions provide patient engagement, mobility, clinical decision support, integrated inbound and outb …
  • Briggs & Stratton Corp (BGG)：企業の財務・戦略的SWOT分析
    Briggs & Stratton Corp (BGG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Aratana Therapeutics Inc (PETX)：企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Tanita Corp：企業の戦略的SWOT分析
    Tanita Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Inotek Pharmaceuticals Corp (RCKT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Inotek Pharmaceuticals Corp (IPC) is a clinical-stage biopharmaceutical company that focus on the discovery and development of novel therapeutics for the treatment of glaucoma and serious diseases of the eye. The company’s trabodenoson is a selective adenosine mimetic that stimulates a speci …
  • Blueprint Medicines Corp (BPMC)：企業の財務・戦略的SWOT分析
    Summary Blueprint Medicines Corp (Blueprint Medicines), formerly Hoyle Pharmaceuticals Inc, discovers and develops precision therapies for the treatment of cancers and rare diseases. The company offers AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST); and GAVRETO (pralse …
  • Protagen AG：企業の製品パイプライン分析2018
    Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment. The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyeliti …
  • Nippon Paint (China) Co Ltd：企業の戦略・SWOT・財務情報
    Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Nippon Paint (China) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TopiVert Ltd-製薬・医療分野：企業M&A・提携分析
    Summary TopiVert Ltd (TopiVert) is a drug development company that offers disease control solutions in inflammatory diseases of the gastrointestinal tract and the eye. The company develops and offers narrow spectrum kinase inhibitors (NSKI) for the treatment of chronic inflammatory diseases of gastr …
  • 4D Molecular Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary 4D Molecular Therapeutics Inc (4D Molecular Therapeutics) is a gene therapy company that deliver genes to specific cells in the body to eradicate rare and large market diseases. The company discovers and develops targeted and proprietary AAV gene therapy vectors and therapeutic products. It …
  • Medison Pharma Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Medison Pharma Ltd (Medison) is a drug company that develops and manufactures medical products. The company's oncology products include vectibix, myocet, aranesp, symphony and coloprint. Its neurology products are avonex, tysabri, fampyra, provigil, stryker, dysport and firdapse. Medison off …
  • Symphogen AS：企業の戦略的SWOT分析
    Symphogen AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Grand Haven Board of Light and Power：企業の戦略的SWOT分析
    Grand Haven Board of Light and Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆